- Active not recruitingPHASE2
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
This study looks at a new drug, AZD9833, for post-menopausal women with advanced breast cancer that's hormone-sensitive (ER-positive) and HER2-negative. It compares AZD9833, taken by mouth, with an existing injected drug, Fulvestrant, to see which is safer and more effective.
For: Advanced ER-Positive HER2-Negative Breast CancerUnited States · Belgium · Canada - Active not recruitingPHASE3
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
This study compares two drug combinations – camizestrant with palbociclib, and anastrozole with palbociclib – for advanced breast cancer. It's for patients whose cancer has specific hormone features and hasn't yet been treated for its advanced stage. The goal is to find a better first treatment.
For: ER-Positive HER2-Negative Breast CancerUnited States · Austria · Belgium - Active not recruitingPHASE1
Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.
This study is looking into a new medicine, AZD9833, for women with advanced breast cancer that is hormone-sensitive (ER+) but not HER2-positive. It's testing AZD9833 alone or with other common cancer drugs to see if it's safe and how well it works.
For: ER+ HER2- Advanced Breast CancerUnited States · Spain · United Kingdom - Active not recruitingPHASE3
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
This study is testing a new drug, AZD9833, for advanced breast cancer. It's for people whose cancer has a specific gene change (ESR1 mutation) and are already on certain treatments. Researchers want to see if adding AZD9833 works better than current medicines.
For: ER-Positive HER2-Negative Breast CancerUnited States · Australia · Austria